JP2002275087A - Antidiabetic medicine and food for preventing diabetes - Google Patents

Antidiabetic medicine and food for preventing diabetes

Info

Publication number
JP2002275087A
JP2002275087A JP2001074766A JP2001074766A JP2002275087A JP 2002275087 A JP2002275087 A JP 2002275087A JP 2001074766 A JP2001074766 A JP 2001074766A JP 2001074766 A JP2001074766 A JP 2001074766A JP 2002275087 A JP2002275087 A JP 2002275087A
Authority
JP
Japan
Prior art keywords
weight
water
jellyfish
food
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001074766A
Other languages
Japanese (ja)
Inventor
Samin En
佐民 袁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mikimoto Pharmaceutical Co Ltd
Original Assignee
Mikimoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikimoto Pharmaceutical Co Ltd filed Critical Mikimoto Pharmaceutical Co Ltd
Priority to JP2001074766A priority Critical patent/JP2002275087A/en
Publication of JP2002275087A publication Critical patent/JP2002275087A/en
Pending legal-status Critical Current

Links

Landscapes

  • Seeds, Soups, And Other Foods (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain an antidiabetic medicine which exhibits an excellent antidiabetic action for diabetes or persons who are not diabetic but have high blood glucose levels. SOLUTION: This antidiabetic medicine contains a water extract of the fruit bodies of Auricularia polytricha or its purified product, or the shell powder of Pinctada fucata.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は天然物で糖尿病に対
して抗糖尿病作用を示す抗糖尿病剤およびその抗糖尿病
剤が配合された予防食品に関する。
TECHNICAL FIELD The present invention relates to an antidiabetic agent which is a natural product and has an antidiabetic action against diabetes, and to a preventive food containing the antidiabetic agent.

【0002】[0002]

【従来の技術】経済の発達に伴い、食生活が向上し、ま
た、清涼飲料をはじめ、甘味料や炭水化物の摂取が必要
な量を越えており、インスリン非依存型糖尿病あるいは
糖尿病とはいえないまでも、血糖値が正常の範囲を逸脱
しつつある人が多い。糖尿病は多くの合併症(網膜症、
腎症、神経症、脳梗塞、心筋梗塞、白内障)を誘発し、
社会的損失は重大な問題である。しかしながら、食生活
を改善することは現代の環境下では困難である。また、
抗糖尿病剤は各種存在するが一般に化学合成品は、効果
は高いものの副作用もあるため、長期の投与には問題が
多い。
2. Description of the Related Art With the development of the economy, dietary habits have improved, and the intake of sweeteners and carbohydrates, including soft drinks, has exceeded the required amount, and it cannot be said that the disease is non-insulin-dependent diabetes or diabetes. Even so, many people have blood sugar levels that are outside the normal range. Diabetes has many complications (retinopathy,
Nephropathy, neuropathy, cerebral infarction, myocardial infarction, cataract)
Social loss is a serious problem. However, improving eating habits is difficult in modern environments. Also,
There are various antidiabetic agents, but in general, chemically synthesized products have high effects but also have side effects, so that there are many problems in long-term administration.

【0003】一方、すでに多年にわたって食用に供さ
れ、人体に対する安全性が確認されている天然物のなか
で、キクラゲ(Auricularia auricula-judae)は新生仔
期にストレプトゾトシンを投与して誘発した糖尿病ラッ
トに対して、血糖値およびインスリン分泌に及ぼす改善
効果が認められている(日本栄養・食糧学会誌、51
巻、第3号、129〜133頁、1998年)。
On the other hand, among natural products which have been used for food for many years and whose safety to the human body has been confirmed, jellyfish (Auricularia auricula-judae) is known to be administered to diabetic rats induced by administering streptozotocin during the neonatal period. On the other hand, an improving effect on blood glucose level and insulin secretion has been recognized (Journal of the Japan Nutrition and Food Society, 51
Vol. 3, No. 129-133, 1998).

【0004】また、アコヤ貝(Pinctada fucata)は、
真珠養殖のため大量に生産されている。このアコヤ貝を
利用した医薬物質として、真珠を加熱することにより得
られる物質が知られている(特開平1−19991
2)。
The pearl oyster (Pinctada fucata) is
Produced in large quantities for pearl farming. As a drug substance utilizing the pearl oyster, a substance obtained by heating a pearl is known (JP-A-1-19991).
2).

【0005】[0005]

【発明が解決しようとする課題】しかしながら、キクラ
ゲに似たアラゲキクラゲ(Auricularia polytricha)
は、食用とした場合に品質面でキクラゲに劣り、また成
分面でも粗タンパク質含有量が約半分であり、同じキク
ラゲ科に属し食用とはなるが、異なった組成を有する天
然物として扱われている。このため、アラゲキクラゲよ
り抗糖尿病剤が得られるかどうか不明であるという問題
があった。アコヤ貝(Pinctada fucata)は真珠採取後
の有効利用が十分になされておらず、また抗糖尿病剤と
しての効果の有無については不明であるという問題があ
った。本発明は、このような問題に対処するためになさ
れたもので、糖尿病あるいは糖尿病とまではいかないが
血糖値が高い人に優れた抗糖尿病作用を示す、アラゲキ
クラゲより得られる抗糖尿病剤、アコヤ貝より得られる
抗糖尿病剤、あるいはこれらを配合した糖尿病予防食品
を提供することを目的とする。
However, Auricularia polytricha resembling a jellyfish
Is inferior to jellyfish in terms of quality when used as food, and has about half the crude protein content in terms of ingredients, belongs to the same jellyfish family and is edible, but is treated as a natural product with a different composition I have. For this reason, there was a problem that it was unclear whether or not an antidiabetic agent could be obtained from A. jellyfish. The pearl oyster (Pinctada fucata) has a problem that its effective utilization after pearl collection has not been sufficiently performed, and it is unclear whether or not it has an effect as an antidiabetic agent. The present invention has been made in order to address such a problem, and has excellent anti-diabetic effects on people with high blood sugar levels, although not diabetes or diabetes. An object of the present invention is to provide an antidiabetic agent obtained from shellfish, or a food for preventing diabetes containing the same.

【0006】[0006]

【課題を解決するための手段】本発明の抗糖尿病剤は、
アラゲキクラゲ(Auricularia polytricha)の子実体の
水抽出物を配合したことを特徴とする。
The anti-diabetic agent of the present invention comprises:
It is characterized by containing an aqueous extract of the fruit body of Auricularia jellyfish (Auricularia polytricha).

【0007】他の抗糖尿病剤は、アラゲキクラゲ(Auri
cularia polytricha)の子実体の水抽出物に由来する水
溶性多糖類を配合したことを特徴とする。また、その水
溶性多糖類が、アラゲキクラゲ(Auricularia polytric
ha)の子実体の水抽出物を水溶性有機溶媒あるいは水溶
性有機溶媒と水の混合溶媒で沈殿処理した沈殿物である
ことを特徴とする。
[0007] Other antidiabetic agents include Auri jellyfish (Auri
water-soluble polysaccharide derived from an aqueous extract of the fruiting body of C. cularia polytricha). Also, the water-soluble polysaccharide is Auricularia polytric
It is characterized in that it is a precipitate obtained by precipitating a water extract of the fruiting body of ha) with a water-soluble organic solvent or a mixed solvent of a water-soluble organic solvent and water.

【0008】また、他の抗糖尿病剤は、アコヤ貝(Pinc
tada fucata)の貝殻粉末を配合したことを特徴とす
る。
Another anti-diabetic agent is pearl oyster (Pinc
tada fucata) shell powder.

【0009】本発明の糖尿病予防食品は、食品中に上記
抗糖尿病剤が単独で、あるいは混合して配合されている
ことを特徴とする。
[0009] The diabetes preventive food of the present invention is characterized in that the above-mentioned antidiabetic agent is incorporated in the food alone or in combination.

【0010】本願発明者は、すでに多年にわたって食用
に供され、人体に対する安全性が確認されている天然物
をスクリーニングして調べた結果、アラゲキクラゲの子
実体から得られる成分に水溶性多糖類がキクラゲから得
られる成分よりも多量に存在することを見出し、また糖
尿病、特にインスリン非依存型糖尿病に対してこの水溶
性多糖類が抗糖尿病作用を有することを見出した。ま
た、アコヤ貝(Pinctadafucata)の貝殻粉末が抗糖尿病
作用を有することを見出した。本発明はこれらの知見に
基づくものである。
The present inventors have screened and examined natural products which have been used for food for many years and have been confirmed to be safe for the human body. As a result, the water-soluble polysaccharide was found to be a component obtained from the fruiting bodies of the jellyfish jellyfish. The present inventors have found that the water-soluble polysaccharide has an anti-diabetic effect on diabetes, particularly non-insulin-dependent diabetes, in a larger amount than the component obtained from Rhododendron. In addition, the inventors have found that shell powder of pearl oyster (Pinctadafucata) has an anti-diabetic effect. The present invention is based on these findings.

【0011】[0011]

【発明の実施の形態】本発明に使用できるアラゲキクラ
ゲの子実体は、培養子実体、天然自生の子実体またはこ
れら子実体が混合したものでもよい。また子実体は市販
の乾燥品、採取してきた生品のいずれも利用できる。ア
ラゲキクラゲの子実体は水で抽出できる。抽出温度は室
温よりも高い温度が効率的に抽出できるため好ましく、
好ましい抽出温度は 50〜100℃である。抽出時間は温度
などによって異なるが、 30 分から 5 時間程度が効率
的に抽出できるため好ましく、抽出効率をさらに上げた
い場合は抽出を数回繰り返す。抽出するために加える水
の量は上記抽出の条件などによって異なるが、アラゲキ
クラゲの子実体 1 重量部に対して 10 〜1000 重量部の
抽出水量が好ましい。 10 重量部未満であると、有効成
分の抽出が不十分であり、 1000 重量部を越えると抽出
物の濃縮や乾燥が困難となる。抽出物は、公知の方法で
濃縮あるいは乾燥物にして抗糖尿病剤あるいはその予防
食品に利用できる。
BEST MODE FOR CARRYING OUT THE INVENTION The fruiting bodies of the jellyfish jellyfish that can be used in the present invention may be cultured fruiting bodies, naturally occurring fruiting bodies, or a mixture of these fruiting bodies. As the fruiting body, either a commercially available dried product or a collected raw product can be used. The fruiting body of the jellyfish jellyfish can be extracted with water. The extraction temperature is preferable because a temperature higher than room temperature can be efficiently extracted,
The preferred extraction temperature is 50-100 ° C. The extraction time varies depending on the temperature, etc., but it is preferable that the extraction time is about 30 minutes to 5 hours because the extraction can be performed efficiently. If the extraction efficiency is to be further increased, repeat the extraction several times. The amount of water to be added varies depending on the conditions of the above extraction, but the amount of water to be extracted is preferably 10 to 1000 parts by weight per 1 part by weight of the fruit body of the mushroom. If the amount is less than 10 parts by weight, extraction of the active ingredient is insufficient, and if it exceeds 1000 parts by weight, concentration and drying of the extract become difficult. The extract can be concentrated or dried by a known method and used as an antidiabetic agent or its preventive food.

【0012】アラゲキクラゲの子実体の水抽出物をさら
に分離精製して、抗糖尿病作用により優れた物質を得る
ことができる。この物質は水抽出物に含まれる高分子量
の水溶性多糖類であることがわかった。上記水抽出物の
分離精製は、低分子量物質を除く方法で精製することが
好ましい。低分子量物質を除く方法としては、水溶性有
機溶媒を用いて精製する方法、カラムクロマトグラフィ
ーを用いて分画する方法、電気泳動法、超遠心法、透析
法等の公知の方法を用いることができる。これらの中で
も、水溶性有機溶媒を用いて精製する方法が簡易な方法
で目的とする物質を得られるため利用価値が高く好まし
い方法である。
[0012] The water extract of the fruit body of the Asteraceae jellyfish can be further separated and purified to obtain a substance having better antidiabetic action. This substance was found to be a high molecular weight water-soluble polysaccharide contained in the water extract. In the separation and purification of the water extract, it is preferable to purify the aqueous extract by a method for removing low molecular weight substances. As a method for removing low molecular weight substances, a known method such as a method of purifying using a water-soluble organic solvent, a method of fractionating using column chromatography, an electrophoresis method, an ultracentrifugation method, or a dialysis method may be used. it can. Among these, the method of purification using a water-soluble organic solvent is a highly useful and preferable method because the target substance can be obtained by a simple method.

【0013】水溶性有機溶媒を用いて精製する方法は、
アラゲキクラゲの子実体の水抽出液に、水溶性有機溶媒
を加えるか、あるいは水溶性有機溶媒と水との混合溶媒
を加えて、水抽出液中に溶解している高分子量物質を沈
殿させて分離精製する方法である。水溶性有機溶媒とし
ては、メタノール、エタノール、ブタノール、イソプロ
ピルアルコールなどの低級一価アルコール類、エチレン
グリコール、グリセリンなどの多価アルコール類、アセ
トンなどの水溶性ケトンなどが利用できる。これらの中
で、エタノールがもっとも好ましい。分離精製された物
質が抗糖尿病剤または糖尿病予防食品原料となり、人が
食するからである。具体的な分離精製方法としては、ア
ラゲキクラゲの子実体の水抽出液に、全体でのエタノー
ル濃度が 50 重量%以上になるようにエタノールを加え
る。これを攪拌し、沈殿物をデカンテーションや遠心分
離等公知の方法を用いて集める。用いた水溶性有機溶媒
が飲用できない種類の場合は充分に有機溶媒を除く操作
を行なう必要があるが、エタノールの場合、用途によっ
ては残留してもなんら問題ないので、用途によって必要
な程度にエタノールあるいは水の除去工程を行なう。
The method for purification using a water-soluble organic solvent is as follows:
A water-soluble organic solvent or a mixed solvent of a water-soluble organic solvent and water is added to an aqueous extract of the fruiting body of the jellyfish jellyfish to precipitate high molecular weight substances dissolved in the aqueous extract. This is a method for separation and purification. Examples of the water-soluble organic solvent include lower monohydric alcohols such as methanol, ethanol, butanol, and isopropyl alcohol, polyhydric alcohols such as ethylene glycol and glycerin, and water-soluble ketones such as acetone. Of these, ethanol is most preferred. This is because the separated and purified substance becomes an antidiabetic agent or a raw material for preventing diabetes and is eaten by humans. As a specific separation and purification method, ethanol is added to an aqueous extract of the fruiting body of the mushroom jellyfish, so that the total ethanol concentration is 50% by weight or more. This is stirred, and the precipitate is collected using a known method such as decantation or centrifugation. If the used water-soluble organic solvent is of a type that cannot be drunk, it is necessary to remove the organic solvent sufficiently, but in the case of ethanol, there is no problem if it remains depending on the application. Alternatively, a water removing step is performed.

【0014】本発明に使用できるアコヤ貝(Pinctada f
ucata)の貝殻粉末は、真珠採取後の貝殻、特に真珠層
を粉砕精製して得られる粉末である。この粉末は、中国
漢方で使用されている真珠粉と略同一組成を有し、真珠
タンパク質(コンキオリン)を含有している。この貝殻
粉末は、粉末状で、あるいは水分散液として抗糖尿病剤
あるいはその予防食品に利用できる。
The pearl oyster (Pinctada f) which can be used in the present invention
The shell powder of ucata) is a powder obtained by crushing and refining a shell, particularly a nacre, after collecting pearls. This powder has substantially the same composition as the pearl powder used in Chinese herbal medicine, and contains pearl protein (conchiolin). The shell powder can be used as an antidiabetic agent or its preventive food in powder form or as an aqueous dispersion.

【0015】また、上記のアラゲキクラゲの子実体の抽
出物、精製物、アコヤ貝の貝殻粉末、またはこれらの混
合物は、必要な他の原料を配合して抗糖尿病剤予防食品
が得られる。本発明の抗糖尿病剤は、食品に含まれる炭
水化物の吸収を抑制し、急激な血糖の上昇を防止する作
用があるので、これらを配合しても味や食感に差が生じ
なければ、健康食品として有用である。健康食品として
は、錠剤、顆粒、あるいは粉末スープ、お茶などの嗜好
品に好適に配合できる。
The extract, purified product, pearl oyster shell powder, or a mixture thereof of the fruit body of the genus Asteraceae can be mixed with other necessary raw materials to obtain an antidiabetic preventive food. The antidiabetic agent of the present invention has an effect of suppressing the absorption of carbohydrates contained in foods and preventing a rapid rise in blood sugar. Useful as food. As a health food, it can be suitably blended with tablets, granules, powdered soups, and other favorite products such as tea.

【0016】[0016]

【実施例】実施例1 中国産アラゲキクラゲの子実体の乾燥物をミキサ−で粉
砕して粉末とした。この粉末に 20 重量倍の水を加えて
沸騰水浴を用いた加熱下に撹拌しつつ、 3 時間抽出処
理をした。その後、遠心分離して抽出残渣を取り除き、
第 1 回目の抽出液を得た。抽出残渣に上記と同様の抽
出処理をさらに 3 回繰り返し、第 2〜4回目の抽出液を
それぞれ得た。第 1〜4 回目の抽出液を合体させて、真
空凍結乾燥して熱水で抽出したアラゲキクラゲの子実体
の水抽出物乾燥粉末を得た。得られた水抽出物乾燥粉末
の収率は、乾燥アラゲキクラゲの子実体に対して 34 重
量%であった。
EXAMPLES Example 1 A dried product of the fruit body of the Chinese jellyfish jellyfish was pulverized with a mixer into powder. The powder was added with 20 times by weight of water, and extracted for 3 hours while stirring under heating using a boiling water bath. After that, centrifugation removes the extraction residue,
The first extract was obtained. The same extraction treatment as above was repeated three more times on the extraction residue to obtain second to fourth extraction liquids. The first to fourth extraction liquids were combined, freeze-dried under vacuum, and extracted with hot water to obtain a water extract dried powder of the fruit body of the jellyfish jellyfish. The yield of the obtained dry powder of the water extract was 34% by weight based on the body of the dried jellyfish.

【0017】実施例1で得られた水抽出物乾燥粉末を以
下に示す抗糖尿病作用試験に供した。インスリン非依存
型糖尿病モデル動物として、KK−A/TaJclマ
ウス(以下、KK−Aマウスという)を用いた。KK
−Aマウスは、ヒトのインスリン非依存型糖尿病に似
た病態を示す自然発症インスリン非依存型糖尿病モデル
動物である。このマウスは通常の飼料を与えるだけで、
正常なマウスと比較してインスリン抵抗性を有し、肥
満、過食、多飲、高血糖、高尿糖、耐糖能低下など特徴
ある諸症状の現れることが知られている。4 週令の雄性
KK−Aマウス(日本クレア(株)、以下同じ)に基
本飼料を与えて 18 日間予備飼育した後、実験に用い
た。基本飼料の配合は、カゼイン20.0重量%、DL−メ
チオニン 0.3重量%、α−コーン澱粉 45.0重量%、シ
ュークロース 20.0重量%、ミネラル混合物(AIN7
6) 3.5重量%、ビタミン混合物(AIN76) 1.0重
量%、重酒石酸コリン 0.2重量%、コーン油 5.0重量
%、およびセルロース 5.0重量%である。
The water extract dried powder obtained in Example 1 was subjected to the following antidiabetic action test. KK- Ay / TaJcl mice (hereinafter referred to as KK- Ay mice) were used as non-insulin-dependent diabetes model animals. KK
-A y mice are spontaneously non-insulin dependent diabetes mellitus model animal exhibiting a condition similar to human non-insulin dependent diabetes mellitus. This mouse only needs to feed normal food,
It is known that mice have insulin resistance as compared with normal mice, and exhibit characteristic symptoms such as obesity, overeating, polydipsia, high blood sugar, high urinary glucose, and decreased glucose tolerance. Four-week-old male KK- Ay mice (Clear Japan Co., Ltd .; same hereafter) were fed a basic diet and preliminarily reared for 18 days before use in the experiment. The basic feed was composed of 20.0% by weight of casein, 0.3% by weight of DL-methionine, 45.0% by weight of α-corn starch, 20.0% by weight of sucrose, and a mineral mixture (AIN7).
6) 3.5% by weight, vitamin mixture (AIN76) 1.0% by weight, choline bitartrate 0.2% by weight, corn oil 5.0% by weight, and cellulose 5.0% by weight.

【0018】マウスを体重および血糖値を基準に 1 群
5 匹として 2 群(投与群、対照群)に分け、実験飼料
でそれぞれ 6 週間飼育した。投与群の実験飼料は、基
本飼料中のセルロースの配合割合を 5.0重量%から 2.0
重量%に減らし、代わりに実施例1で得られた水抽出物
乾燥粉末を 3.0重量%添加した飼料であり、対照群の実
験飼料は基本飼料そのままである。飼育環境は、室温 2
3〜25℃、相対湿度 50〜60 %、 12 時間の明暗周期の
条件下、底が網目のステンレス製懸垂ケ−ジ内で個別飼
育した。実験期間中に、餌と飲料水は自由に摂取させ
た。ただし、以下に記載する測定時には各測定方法に記
載のあるように飼料摂取を制限した。
[0018] One group of mice based on body weight and blood glucose level
Five animals were divided into two groups (administration group and control group), each of which was bred on experimental diet for 6 weeks. The experimental feed in the treatment group was adjusted from 5.0% by weight to 2.0% of cellulose in the basic feed.
In this case, the feed was reduced to 3.0% by weight, and instead the dry powder of the water extract obtained in Example 1 was added in an amount of 3.0% by weight. Rearing environment is room temperature 2
The animals were individually raised in a stainless steel suspension cage with a mesh bottom at a temperature of 3 to 25 ° C., a relative humidity of 50 to 60%, and a light / dark cycle of 12 hours. Food and drinking water were available ad libitum during the experiment. However, during the measurement described below, feed intake was restricted as described in each measurement method.

【0019】実験期間中に、マウスの体重、飼料摂取
量、水摂取量、空腹時血糖値、食後血糖値および尿糖値
を測定した。測定結果は各群の 5 匹の平均値と標準誤
差を用いて、[平均値±標準誤差]で表す。表中、星印
[*]を付した数値は、Student−t検定で対照
に対し、p< 0.05 の有意差をそれぞれ示すものであ
る。
During the experiment, mice were measured for body weight, feed intake, water intake, fasting blood glucose, postprandial blood glucose and urinary glucose. The measurement results are expressed as [mean ± standard error] using the average value and standard error of 5 animals in each group. In the table, numerical values marked with an asterisk [*] indicate significant differences of p <0.05 with respect to the control in the Student-t test, respectively.

【0020】(1)体重、飼料摂取量、水摂取量の測定 マウスの体重を毎週 1 回測定し、飼料摂取量および水
摂取量を毎日測定した。実験開始時体重、実験終了時体
重、平均飼料摂取量、平均水摂取量を表1に示す。
(1) Measurement of Body Weight, Feed Intake, and Water Intake Mice were weighed once a week, and feed intake and water intake were measured daily. Table 1 shows the body weight at the start of the experiment, the body weight at the end of the experiment, the average feed intake, and the average water intake.

【0021】(2)空腹時血糖値の測定 実験飼料投与前日( 0 日)および投与 7 日、 14 日、
21 日、 28 日、 35日後に、マウスを 5 時間絶食させ
て、無麻酔下で、尾静脈より採血し、直ちに遠心分離し
て血漿を分取した。血漿中のグルコ−ス濃度(血糖値)
をグルコースCII−テストワコー(和光純薬工業
(株)、以下同じ)を用いて測定した。その結果を表1
に示す。
(2) Measurement of Fasting Blood Glucose Level The day before administration of experimental feed (day 0) and on days 7 and 14 of administration
After 21 days, 28 days and 35 days, the mice were fasted for 5 hours, blood was collected from the tail vein under anesthesia, and immediately centrifuged to collect plasma. Glucose concentration in plasma (blood sugar level)
Was measured using glucose CII-Test Wako (Wako Pure Chemical Industries, Ltd .; the same applies hereinafter). Table 1 shows the results.
Shown in

【0022】(3)食後血糖値の測定 マウスを実験飼料で 5 週間飼育した後、 5 時間絶食さ
せて、 30 分間 2g/kg(体重)の糖質に相当するそれぞ
れの実験飼料を摂取させた。食後 1 時間および 2 時間
に無麻酔下で、尾静脈より採血し、直ちに遠心分離して
血漿を分取した。血漿中のグルコ−ス濃度(血糖値)を
グルコースCII−テストワコーを用いて測定した。その
結果を表1に示す。
(3) Measurement of postprandial blood glucose level After breeding the mice on the experimental diet for 5 weeks, they were fasted for 5 hours and ingested each experimental diet corresponding to 2 g / kg (body weight) of carbohydrate for 30 minutes. . One hour and two hours after the meal, blood was collected from the tail vein under anesthesia and immediately centrifuged to collect plasma. Glucose concentration (blood sugar level) in plasma was measured using Glucose CII-Test Wako. Table 1 shows the results.

【0023】(4)尿糖値の測定 マウスを実験飼料で 4 週間飼育した後、 24 時間尿を
採取し、尿中へ排泄されたグルコ−ス量を求めた。尿中
のグルコ−ス量(尿糖値)をグルコースCII−テストワ
コーを用いて測定した。その結果を表1に示す。
(4) Measurement of Urine Sugar Level After the mice were bred for 4 weeks on the experimental feed, urine was collected for 24 hours, and the amount of glucose excreted in the urine was determined. The amount of glucose in urine (urine sugar level) was measured using Glucose CII-Test Wako. Table 1 shows the results.

【0024】[0024]

【表1】 [Table 1]

【0025】表1の実験結果をまとめると、アラゲキク
ラゲの子実体の熱水抽出物はインスリン非依存型糖尿病
に対して、過食、多飲の改善効果、空腹時血糖の上昇抑
制効果、食後高血糖の抑制効果、尿糖排泄の減少効果を
有することがわかった。
To summarize the experimental results in Table 1, the hot-water extract of the fruit body of Asterella jellyfish improves overeating, polydipsia, suppresses fasting blood glucose elevation, and increases postprandial elevation of insulin-independent diabetes. It was found to have an effect of suppressing blood sugar and an effect of reducing urinary glucose excretion.

【0026】実施例2 実施例1の凍結乾燥する前の抽出液に 4 倍量(V/V)の
95 %のエタノ−ルを加え、生じた沈殿物を遠心分離に
より採取した。その沈殿物を水に溶解し、透析膜(商品
名:セルロースチューブ 30/32、三光純薬
(株))に入れ、流水中にて 48 時間透析処理した。そ
の残留液(透析膜の内側の液)を真空凍結乾燥して、エ
タノ−ルで分離精製した沈殿物を得た。この沈殿物は水
溶性多糖類であった。この水溶性多糖類の収率は、乾燥
アラゲキクラゲの子実体に対して 24 重量%であった。
Example 2 A four-fold amount (V / V) was added to the extract before freeze-drying of Example 1.
95% ethanol was added and the resulting precipitate was collected by centrifugation. The precipitate was dissolved in water, placed in a dialysis membrane (trade name: Cellulose tube 30/32, Sanko Junyaku Co., Ltd.), and dialyzed in running water for 48 hours. The remaining solution (the solution inside the dialysis membrane) was freeze-dried in vacuo to obtain a precipitate separated and purified with ethanol. This precipitate was a water-soluble polysaccharide. The yield of this water-soluble polysaccharide was 24% by weight based on the fruit body of the dried jellyfish jellyfish.

【0027】実施例2で得られた水溶性多糖類を以下に
示す抗糖尿病作用試験に供した。4 週令の雄性KK−A
マウスに実施例1の試験で用いた基本飼料を与えて、
7 日間予備飼育した後、実験に用いた。
The water-soluble polysaccharide obtained in Example 2 was subjected to the following antidiabetic activity test. 4-week-old male KK-A
Y mice were fed the basic diet used in the test of Example 1,
After 7 days of preliminary breeding, they were used for experiments.

【0028】マウスを体重および血糖値を基準に 1 群
8 匹として 2 群(投与群、対照群)に分け、実験飼料
でそれぞれ 8 週間、実施例1と同一の飼育環境で飼育
した。投与群の実験飼料は、基本飼料中のセルロースの
配合割合を 5.0重量%から 3.0重量%に減らし、代わり
に実施例2で得られた水溶性多糖類を 2.0重量%添加し
た飼料であり、対照群の実験飼料は基本飼料そのままで
ある。
One group of mice based on body weight and blood glucose level
Eight animals were divided into two groups (administration group and control group), and reared on the experimental feed for 8 weeks in the same breeding environment as in Example 1. The experimental feed of the administration group was a feed in which the blending ratio of cellulose in the basic feed was reduced from 5.0% by weight to 3.0% by weight, and 2.0% by weight of the water-soluble polysaccharide obtained in Example 2 was added instead. The experimental diet of the group is the same as the basic diet.

【0029】実験期間中に、マウスの体重、飼料摂取
量、水摂取量、空腹時血糖値、尿糖値、非絶食血糖値お
よび小腸二糖類水解酵素活性を測定し、耐糖能試験およ
びインスリン耐量試験を行なった。測定結果は各群の 8
匹の平均値と標準誤差を用いて、[平均値±標準誤
差]で表す。表中、星印[*]を付した数値は、Stu
dent−t検定で対照に対し、p< 0.05 の有意差を
それぞれ示すものである。
During the experimental period, the body weight, feed intake, water intake, fasting blood glucose level, urine glucose level, non-fasting blood glucose level and small intestinal disaccharide hydrolase activity of the mice were measured, and the glucose tolerance test and insulin tolerance were measured. The test was performed. The measurement results were 8 for each group.
Using the average value and the standard error of each animal, it is expressed as [mean ± standard error]. In the table, numerical values marked with an asterisk [*] are Stu
The results show a significant difference of p <0.05 with respect to the control by the dent-t test.

【0030】体重、飼料摂取量、水摂取量を実施例1と
同様の方法で測定した。また、空腹時血糖値を実験飼料
投与前日( 0 日)および投与 14 日、 28 日、 49 日
後に、実施例1と同様の方法で測定した。その結果を表
2に示す。
The body weight, feed intake and water intake were measured in the same manner as in Example 1. In addition, the fasting blood glucose level was measured by the same method as in Example 1 on the day before the administration of the experimental feed (day 0) and on days 14, 28 and 49 after administration. Table 2 shows the results.

【0031】マウスを実験飼料で 4 週間飼育した後、
実施例1と同様の方法で尿糖値を測定した。その結果を
表2に示す。
After breeding the mice on the experimental diet for 4 weeks,
The urinary sugar level was measured in the same manner as in Example 1. Table 2 shows the results.

【0032】(5)耐糖能試験 マウスを実験飼料で 5 週間飼育した後、 20 時間絶食
させ、グルコ−スを 1g/kg(体重)の投与量で腹腔内に
投与し、グルコ−ス投与直前および投与 30 分、 60
分、120 分後に無麻酔下で尾静脈より採血し、直ちに遠
心分離して血漿を分取した。血漿中のグルコ−ス濃度
(血糖値)をグルコースCII−テストワコーを用いて測
定した。その結果を表2に示す。また、グルコ−ス投与
直前および投与 30 分、 60 分、120 分後の血糖値の和
を血糖値総和とし、その結果を表2に示す。
(5) Glucose Tolerance Test After breeding mice for 5 weeks on an experimental feed, they were fasted for 20 hours, and glucose was intraperitoneally administered at a dose of 1 g / kg (body weight) immediately before glucose administration. And administration 30 minutes, 60
After 120 minutes and 120 minutes, blood was collected from the tail vein under anesthesia, and immediately centrifuged to collect plasma. Glucose concentration (blood sugar level) in plasma was measured using Glucose CII-Test Wako. Table 2 shows the results. The sum of the blood glucose levels immediately before and 30 minutes, 60 minutes, and 120 minutes after the administration of glucose was defined as the total blood glucose level. The results are shown in Table 2.

【0033】(6)インスリン耐量試験 マウスを実験飼料で 7 週間飼育した後、 24 時間絶食
させ、インスリン(日本イーライリリー(株))を 0.5
U/kg(体重)の投与量で皮下に投与し、インスリン投与
直前および投与 30 分、 60 分、 90 分後に無麻酔下で
尾静脈より採血し、直ちに遠心分離して血漿を分取し
た。血漿中のグルコ−ス濃度(血糖値)をグルコースC
II−テストワコーを用いて測定した。その結果を表2に
示す。
(6) Insulin Tolerance Test After breeding mice for 7 weeks on the experimental feed, they were fasted for 24 hours, and insulin (Nippon Eli Lilly Co., Ltd.)
U / kg (body weight) was administered subcutaneously, blood was collected from the tail vein under anesthesia immediately before insulin administration, and at 30, 60, and 90 minutes after administration, and immediately centrifuged to collect plasma. The glucose concentration (blood sugar level) in plasma
It measured using II-Test Wako. Table 2 shows the results.

【0034】(7)非絶食血糖値の測定 マウスを実験飼料で 8 週間飼育した後、非絶食、無麻
酔下で断頭して採血し、直ちに遠心分離して血清を分取
した。血清中のグルコ−ス濃度(血糖値)をグルコース
CII−テストワコーを用いて測定した。その結果を表2
に示す。
(7) Measurement of non-fasting blood glucose level After breeding mice for 8 weeks on an experimental feed, blood was collected by decapitation under non-fasting and non-anesthesia, and blood was immediately collected by centrifugation. The glucose concentration (blood sugar level) in the serum was measured using Glucose CII-Test Wako. Table 2 shows the results.
Shown in

【0035】糖尿病は腸管の機能に非常に大きな変化を
もたらす。小腸の二糖類水解酵素活性は増大し、消化は
速められ、血流への糖質の吸収は増大することが知られ
ている。このため、本発明に係わるアラゲキクラゲの子
実体の抽出物についてKK−Aマウスの小腸二糖類水
解酵素活性の抑制作用を明らかにするべく、以下の検討
を行なった。
Diabetes causes very large changes in intestinal function. It is known that disaccharide hydrolase activity in the small intestine is increased, digestion is accelerated, and absorption of carbohydrates into the bloodstream is increased. For this reason, the following examination was carried out to clarify the inhibitory effect of the extract of the fruit body of the mushroom jellyfish according to the present invention on the intestinal disaccharide hydrolase activity of KK- Ay mice.

【0036】(8)小腸二糖類水解酵素活性の測定 マウスを実験飼料で 8 週間飼育した後、非絶食、無麻
酔下で断頭、屠殺し、全小腸を常法に従って摘出した。
マウスの空腸の内壁の粘膜を採取し、これに 10mM リン
酸カリウム緩衝液(pH 7.0 )の中でホモジナイズ
し、遠心分離(2,000rpm、 10 分、 4 ℃)で沈殿物を
除去後、粗酵素液を得た。この粗酵素液を以下のスクラ
ーゼ、マルターゼ、イソマルターゼ活性の測定に供し
た。
(8) Measurement of Intestinal Disaccharide Hydrolase Activity The mice were bred for 8 weeks on an experimental diet, then decapitated and sacrificed under non-fasting and non-anesthetized conditions, and the entire small intestine was removed in a usual manner.
The mucous membrane of the inner wall of the jejunum of the mouse is collected, homogenized in 10 mM potassium phosphate buffer (pH 7.0), and the precipitate is removed by centrifugation (2,000 rpm, 10 minutes, 4 ° C). A liquid was obtained. This crude enzyme solution was subjected to the following measurements of sucrase, maltase, and isomaltase activities.

【0037】調製した粗酵素液に基質溶液として 0.1M
マレイン酸ナトリウム緩衝液(pH5.8 )に溶解した 2
8mM シュークロースあるいは 28mM マルトースあるいは
2.8mM イソマルトースをそれぞれ加え、 37℃、 1 時
間反応させた後、沸騰水浴中で 3 分間加熱して反応を
停止し、酵素反応で生じたグルコースの量をグルコース
CII―テストワコーを用いて測定した。得られた結果を
表2に示す。二糖類水解酵素活性は粗酵素液中のタンパ
ク質 1mg 当たりの酵素が 1 時間に水解する基質量をμ
mo1 の単位で表した。なお、粗酵素液のタンパク質量
は、ウシ血清アルブミンを標準とし、Lowry法で測
定した。
The prepared crude enzyme solution was used as a substrate solution at 0.1 M
2 dissolved in sodium maleate buffer (pH 5.8)
8mM sucrose or 28mM maltose or
After adding 2.8 mM isomaltose and reacting at 37 ° C for 1 hour, the reaction was stopped by heating in a boiling water bath for 3 minutes, and the amount of glucose produced by the enzyme reaction was measured using a glucose CII-Test Wako did. Table 2 shows the obtained results. Disaccharide hydrolase activity is the amount of enzyme hydrolyzed in 1 hour per 1 mg of protein in crude enzyme solution.
Expressed in mo1 units. The protein amount of the crude enzyme solution was measured by the Lowry method using bovine serum albumin as a standard.

【0038】[0038]

【表2】 [Table 2]

【0039】表2の実験結果をまとめると、アラゲキク
ラゲの子実体の水溶性多糖類はインスリン非依存型糖尿
病に対して、過食、多飲の改善効果、空腹時血糖の上昇
抑制効果、尿糖排泄の減少効果、耐糖能低下の改善効
果、インスリン抵抗性の改善効果、小腸二糖類水解酵素
活性の抑制効果を有することがわかった。
To summarize the experimental results in Table 2, the water-soluble polysaccharides of the fruiting bodies of the jellyfish jellyfish have the effect of improving overeating, polydipsia, suppressing the increase in fasting blood glucose, and urinary glucose against non-insulin-dependent diabetes mellitus. It was found to have an effect of reducing excretion, an effect of improving glucose tolerance, an effect of improving insulin resistance, and an effect of suppressing intestinal disaccharide hydrolase activity.

【0040】KK−Aマウスに対して、糖尿病の発症
の初期段階から本発明に係わるアラゲキクラゲの子実体
の抽出物を含む飼料を投与すると、飼料の中にアラゲキ
クラゲの熱水抽出物の投与量は 3 %、水溶性多糖類の
投与量は 2 %であっても、十分に糖尿病の進行を抑え
られることが明らかになった。また、アラゲキクラゲの
熱水抽出物または水溶性多糖類が投与されたKK−A
マウスを観察したところ、投与中および投与後もマウス
に副作用は現れず、急性毒性が認められなかった。な
お、ヒトの感受性はマウスのそれに比べて高いので、さ
らに、本発明に係わるアラゲキクラゲの子実体の抽出物
をヒトに投与する場合には、上記投与量以下であっても
有効であると推測できる。
KK-AyOnset of diabetes in mice
From the early stage of the present invention
When a feed containing the extract of
The dose of jellyfish hot water extract is 3%,
Even at a dose of 2%, it sufficiently suppresses the progress of diabetes
It became clear that it could be done. Also, jellyfish jellyfish
KK-A administered with hot water extract or water-soluble polysaccharide y
When the mice were observed, the mice were observed during and after administration.
Showed no side effects and no acute toxicity was observed. What
Because the sensitivity of humans is higher than that of mice,
Furthermore, the extract of the fruiting body of the jellyfish jellyfish according to the present invention
When administered to humans, even if the dose is less than the above
Can be inferred to be effective.

【0041】実施例3 アコヤ貝(Pinctada fucata)の貝殻粉末として、市販
の粉末(御木本製薬株式会社製:ベタカルク)を用いて
以下に示す抗糖尿病作用試験に供した。インスリン非依
存型糖尿病モデル動物として、KK−Aマウスを用い
た。4 週令の雄性KK−Aマウス(日本クレア
(株)、以下同じ)に基本飼料を与えて 7 日間予備飼
育した後、尿糖を示したマウスを体重および血糖値を基
準に 2 群(対照群:n=9 ;ベタカルク群:n= 11
)に分けた。対照群では引き続いて実施例1で用いた
基本飼料(対照飼料)を与え、ベタカルク群では基本飼
料中のセルロースの配合割合を 5.0重量%から 2.0重量
%に減らし、代わりにベタカルクを 3.0重量%添加した
飼料を与えて飼育した。飼育環境は、室温 23〜25℃、
相対温度 50〜60%の条件下、底が網目のステンレス製
懸垂ケージ内で個別飼育した。実験期間中に、飼料と飲
料水は自由に摂取させた。ただし、以下に記載する測定
時には各測定の方法に記載のあるように飼料摂取を制限
した。
Example 3 As a shell powder of pearl oyster (Pinctada fucata), a commercially available powder (Betacalc, manufactured by Mikimoto Pharmaceutical Co., Ltd.) was used for the following antidiabetic test. KK- Ay mice were used as non-insulin dependent diabetes model animals. Four-week-old male KK- Ay mice (CLEA Japan, same hereafter) were fed with a basic diet and preliminarily reared for 7 days, and then two groups of mice showing urinary glucose were determined based on body weight and blood glucose level. Control group: n = 9; Betacalc group: n = 11
). In the control group, the basic feed (control feed) used in Example 1 was subsequently given, and in the beta-calc group, the blending ratio of cellulose in the basic feed was reduced from 5.0% by weight to 2.0% by weight, and instead, 3.0% by weight of beta-calc was added. The feed was fed and raised. The breeding environment is room temperature 23-25 ℃,
They were individually housed in stainless steel hanging cages with a mesh bottom under the condition of a relative temperature of 50 to 60%. Food and drinking water were available ad libitum during the experiment. However, during the measurement described below, feed intake was restricted as described in each measurement method.

【0042】実験期間中に、マウスの体重、飼料摂取
量、飲水量、 6 時間空腹時血糖値、および尿糖排泄量
を測定した。測定結果は、各実験群(対照群:n=9 ;
ベタカルク群:n= 11 )の平均値と標準誤差を用い
て、[平均値±標準誤差]で表す。表中、星印[*]を
付した数値は、Student−t検定で対照に対し、
p< 0.05 の有意差をそれぞれ示すものである。
During the experiment, the body weight, feed intake, drinking water, 6-hour fasting blood glucose level, and urinary glucose excretion of the mice were measured. The measurement results were obtained for each experimental group (control group: n = 9;
The average value and the standard error of the beta-calc group: n = 11) are used to represent [average value ± standard error]. In the table, the numerical value with an asterisk [*] indicates a value that was compared with the control in the Student-t test.
It shows the significant difference of p <0.05, respectively.

【0043】(1)体重、飼料摂取量および飲水量の測
定 マウスの体重を毎週測定し、飼料摂取量を毎日測定し
た。飲水量の測定は実験飼料投与 4 週後の 5 週目、 6
週目に行なった。飲水量は毎週 48 時間おきに測定し
て、 1 日ごとの量を算出した。結果を表3に示す。
(1) Measurement of Body Weight, Feed Intake, and Drinking Water Mice were weighed weekly, and feed intake was measured daily. Water consumption was measured at 5 weeks and 4 weeks after administration of experimental feed.
Performed in the week. Water consumption was measured every 48 hours every week, and daily amount was calculated. Table 3 shows the results.

【0044】(2) 6 時間空腹時血糖値の測定 6 時間空腹時血糖値の測定は実験飼料投与前日および投
与 2、 4、 6 週後に行なった。マウスを 6 時間絶食し
た後、無麻酔下で、尾静脈より採血し、直ちに遠心分離
して血漿を分取した。血漿中のグルコース濃度(血糖
値)をグルコースCII−テストワコー(和光純薬工業
(株))を用いて測定した。結果を表3に示す。
(2) Measurement of 6-hour fasting blood glucose level The measurement of 6-hour fasting blood glucose level was performed the day before the administration of the experimental feed and 2, 4, and 6 weeks after the administration. After the mice were fasted for 6 hours, blood was collected from the tail vein under anesthesia and immediately centrifuged to separate the plasma. Glucose concentration (blood sugar level) in plasma was measured using Glucose CII-Test Wako (Wako Pure Chemical Industries, Ltd.). Table 3 shows the results.

【0045】(4)尿糖排泄量の測定 実験飼料を 6 週間投与した後、マウスの 24 時間尿を
採取し、尿中へ排泄されたグルコース量を求めた。尿中
のグルコース量(尿糖値)はグルコースCII−テスト
ワコーを用いて測定した。結果を表3に示す。
(4) Measurement of urinary glucose excretion After the experimental feed was administered for 6 weeks, urine was collected from the mice for 24 hours, and the amount of glucose excreted in the urine was determined. The amount of glucose in urine (urine sugar level) was measured using glucose CII-Test Wako. Table 3 shows the results.

【0046】[0046]

【表3】 [Table 3]

【0047】表3の結果をまとめると、アコヤ貝の貝殻
粉末は、飲水量の減少効果、血糖の上昇抑制効果および
尿糖排泄の減少効果を有することがわかった。
Summarizing the results in Table 3, it was found that the pearl oyster shell powder had an effect of reducing water consumption, an effect of suppressing an increase in blood sugar, and an effect of decreasing urinary glucose excretion.

【0048】アラゲキクラゲの子実体の抽出物、または
アコヤ貝の貝殻粉末をそれぞれ単独で、または混合物と
して食品類に配合することで、糖尿病予防食品が得られ
る。以下、糖尿病予防食品の具体例について説明する。
An anti-diabetic food can be obtained by blending the extract of the fruit body of the mushroom jellyfish, or the shell powder of the pearl oyster, alone or as a mixture with foods. Hereinafter, specific examples of the diabetes prevention food will be described.

【0049】 実施例4 健康食品1(錠剤)の配合割合 A:アラゲキクラゲの子実体の抽出物 50 重量% B:デキストリン 25 重量% C:結晶セルロース 22.5 重量% D:ショ糖脂肪酸エステル 2 重量% E:デンプン 0.5 重量% A〜Cの各成分を秤量し、流動層造粒機でE成分を結合
剤溶液として顆粒化する。その後D成分を加え均一に混
合し打錠機で錠剤とする。
Example 4 Blending ratio of health food 1 (tablet) A: 50% by weight of extract of the fruiting body of Asteraceae jellyfish B: 25% by weight of dextrin C: 22.5% by weight of crystalline cellulose D: 2% by weight of sucrose fatty acid ester E: 0.5% by weight of starch Each component of AC is weighed, and the component E is granulated as a binder solution by a fluidized bed granulator. Thereafter, the D component is added and uniformly mixed, and made into tablets by a tableting machine.

【0050】 実施例5 健康食品2(顆粒)の配合割合 A:アラゲキクラゲの子実体の抽出物 50 重量% B:エリスリトール 30 重量% C:結晶セルロース 18 重量% D:ショ糖脂肪酸エステル 2 重量% E:デンプン 0.5 重量% A〜Cの各成分を秤量し、流動層造粒機でE成分を結合
剤溶液として顆粒化する。その後D成分を加え均一に混
合し顆粒とする。
Example 5 Mixing ratio of health food 2 (granules) A: extract of the fruiting body of Asteraceae jellyfish 50% by weight B: erythritol 30% by weight C: crystalline cellulose 18% by weight D: sucrose fatty acid ester 2% by weight E: 0.5% by weight of starch Each component of AC is weighed, and the component E is granulated as a binder solution by a fluidized bed granulator. Thereafter, the D component is added and uniformly mixed to obtain granules.

【0051】 実施例6 スープ1(粉末スープ)の配合割合 A:アラゲキクラゲの子実体の抽出物 30 重量% B:大豆タンパク 25 重量% C:粉末油脂 13 重量% D:ブイヨン 11 重量% E:食塩 6 重量% F:増粘剤(グァーガム) 5 重量% G:乳タンパク 5 重量% H:調味料(アミノ酸等) 3 重量% I:香料 2 重量% A〜Iの各成分を秤量し均一に混合して粉末スープとす
る。
Example 6 Mixing Ratio of Soup 1 (Powdered Soup) A: 30 wt% extract of the fruit body of the jellyfish jellyfish B: 25 wt% of soybean protein C: powdered fat 13 wt% D: broth 11 wt% E: Salt 6% by weight F: Thickener (guar gum) 5% by weight G: Milk protein 5% by weight H: Seasoning (amino acid etc.) 3% by weight I: Flavor 2% by weight Weigh each component of A to I and uniformly Mix to form a powdered soup.

【0052】 実施例7 お茶1(粉末タイプ)の配合割合 A:アラゲキクラゲの子実体の抽出物 30 重量% B:バナバ茶 25 重量% C:ハト麦茶 25 重量% D:紅茶 20 重量% A〜Dの各成分を秤量し均一に混合して粉末とする。Example 7 Mixing ratio of tea 1 (powder type) A: 30 wt% extract of the fruiting body of Asteraceae jellyfish B: 25 wt% of banaba tea C: 25 wt% of barley tea D: 20 wt% of black tea Each component of D is weighed and uniformly mixed to obtain a powder.

【0053】 実施例8 健康食品3(錠剤)の配合割合 A:アコヤ貝貝殻粉末 50 重量% B:デキストリン 25 重量% C:結晶セルロース 22.5 重量% D:ショ糖脂肪酸エステル 2 重量% E:デンプン 0.5 重量% A〜Cの各成分を秤量し、流動層造粒機でE成分を結合
剤溶液として顆粒化する。その後D成分を加え均一に混
合し打錠機で錠剤とする。
Example 8 Mixing ratio of health food 3 (tablet) A: 50% by weight of pearl oyster shell powder B: 25% by weight of dextrin C: 22.5% by weight of crystalline cellulose D: 2% by weight of sucrose fatty acid ester E: Starch 0.5 Each component of weight% AC is weighed, and the component E is granulated as a binder solution by a fluid bed granulator. Thereafter, the D component is added and uniformly mixed, and made into tablets by a tableting machine.

【0054】 実施例9 健康食品4(顆粒)の配合割合 A:アコヤ貝貝殻粉末 50 重量% B:エリスリトール 30 重量% C:結晶セルロース 17.5 重量% D:ショ糖脂肪酸エステル 2 重量% E:デンプン 0.5 重量% A〜Cの各成分を秤量し、流動層造粒機でE成分を結合
剤溶液として顆粒化する。その後D成分を加え均一に混
合し顆粒とする。
Example 9 Mixing ratio of health food 4 (granules) A: pearl oyster shell powder 50% by weight B: erythritol 30% by weight C: crystalline cellulose 17.5% by weight D: sucrose fatty acid ester 2% by weight E: starch 0.5 Each component of weight% AC is weighed, and the component E is granulated as a binder solution by a fluid bed granulator. Thereafter, the D component is added and uniformly mixed to obtain granules.

【0055】 実施例10 スープ2(粉末スープ)の配合割合 A:アコヤ貝貝殻粉末 30 重量% B:大豆タンパク 25 重量% C:粉末油脂 13 重量% D:ブイヨン 11 重量% E:食塩 6 重量% F:増粘剤(グァーガム) 5 重量% G:乳タンパク 5 重量% H:調味料(アミノ酸等) 3 重量% I:香料 2 重量% A〜Iの各成分を秤量し均一に混合して粉末スープとす
る。
Example 10 Mixing ratio of soup 2 (powder soup) A: pearl oyster shell powder 30% by weight B: soy protein 25% by weight C: powdered fat 13% by weight D: bouillon 11% by weight E: salt 6% by weight F: Thickener (guar gum) 5% by weight G: Milk protein 5% by weight H: Seasoning (amino acids, etc.) 3% by weight I: Flavor 2% by weight A to I components are weighed and uniformly mixed to powder Soup.

【0056】 実施例11 お茶2(粉末タイプ)の配合割合 A:アコヤ貝貝殻粉末 30 重量% B:バナバ茶 25 重量% C:ハト麦茶 25 重量% D:紅茶 20 重量% A〜Dの各成分を秤量し均一に混合して粉末とする。Example 11 Mixing ratio of tea 2 (powder type) A: pearl oyster shell powder 30% by weight B: banaba tea 25% by weight C: pigeon barley tea 25% by weight D: black tea 20% by weight Each component of A to D Are weighed and uniformly mixed to obtain a powder.

【0057】 実施例12 健康食品5(錠剤)の配合割合 A:アラゲキクラゲの子実体の抽出物 25 重量% B:アコヤ貝貝殻粉末 25 重量% C:デキストリン 25 重量% D:結晶セルロース 22.5 重量% E:ショ糖脂肪酸エステル 2 重量% F:デンプン 0.5 重量% A〜Dの各成分を秤量し、流動層造粒機でF成分を結合
剤溶液として顆粒化する。その後E成分を加え均一に混
合し打錠機で錠剤とする。
Example 12 Mixing ratio of health food 5 (tablet) A: 25% by weight of an extract of the fruit body of a jellyfish jellyfish B: 25% by weight of pearl oyster shell powder 25% by weight of dextrin D: 22.5% by weight of crystalline cellulose E: 2% by weight of sucrose fatty acid ester F: 0.5% by weight of starch Each of the components A to D is weighed, and the F component is granulated as a binder solution by a fluid bed granulator. Thereafter, the E component is added and uniformly mixed, and made into tablets by a tableting machine.

【0058】 実施例13 健康食品6(顆粒)の配合割合 A:アラゲキクラゲの子実体の抽出物 25 重量% B:アコヤ貝貝殻粉末 25 重量% C:エリスリトール 30 重量% D:結晶セルロース 17.5 重量% E:ショ糖脂肪酸エステル 2 重量% F:デンプン 0.5 重量% A〜Dの各成分を秤量し、流動層造粒機でF成分を結合
剤溶液として顆粒化する。その後E成分を加え均一に混
合し顆粒とする。
Example 13 Blending ratio of health food 6 (granules) A: Extract of the fruit body of Asteraceae jellyfish 25% by weight B: Pearl oyster shell powder 25% by weight C: Erythritol 30% by weight D: Crystalline cellulose 17.5% by weight E: 2% by weight of sucrose fatty acid ester F: 0.5% by weight of starch Each of the components A to D is weighed, and the F component is granulated as a binder solution by a fluid bed granulator. Thereafter, the E component is added and uniformly mixed to obtain granules.

【0059】 実施例14 スープ3(粉末スープ)の配合割合 A:アラゲキクラゲの子実体の抽出物 15 重量% B:アコヤ貝貝殻粉末 15 重量% C:大豆タンパク 25 重量% D:粉末油脂 13 重量% E:ブイヨン 11 重量% F:食塩 6 重量% G:増粘剤(グァーガム) 5 重量% H:乳タンパク 5 重量% I:調味料(アミノ酸等) 3 重量% J:香料 2 重量% A〜Jの各成分を秤量し均一に混合して粉末スープとす
る。
Example 14 Mixing Ratio of Soup 3 (Powdered Soup) A: Extract of the fruit body of Asteraceae jellyfish 15% by weight B: Pearl oyster shell powder 15% by weight C: Soy protein 25% by weight D: Powdered fat and oil 13% by weight % E: Bouillon 11% by weight F: Salt 6% by weight G: Thickener (guar gum) 5% by weight H: Milk protein 5% by weight I: Seasonings (amino acids, etc.) 3% by weight J: Flavor 2% by weight A ~ Each component of J is weighed and uniformly mixed to obtain a powdered soup.

【0060】 実施例15 お茶3(粉末タイプ)の配合割合 A:アラゲキクラゲの子実体の抽出物 15 重量% B:アコヤ貝貝殻粉末 15 重量% C:バナバ茶 25 重量% D:ハト麦茶 25 重量% E:紅茶 20 重量% A〜Eの各成分を秤量し均一に混合して粉末とする。Example 15 Mixing Ratio of Tea 3 (Powder Type) A: Extract of the fruit body of Asteraceae jellyfish 15% by weight B: Akoya shell powder 15% by weight C: Banaba tea 25% by weight D: Pigeon barley tea 25% by weight % E: Black tea 20% by weight Each of the components A to E is weighed and uniformly mixed to obtain a powder.

【0061】実施例4から実施例15の各糖尿病予防食
品は、味および食感もアラゲキクラゲの子実体の抽出物
およびアコヤ貝貝殻粉末を配合しない食品と同一であっ
た。また、実施例1から実施例3の実験結果から、これ
らを配合した食品は糖尿病予防食品として優れている。
Each of the anti-diabetic foods of Examples 4 to 15 had the same taste and texture as the foods not containing the extract of the fruit body of Arauki jellyfish and the pearl oyster shell powder. Also, from the experimental results of Examples 1 to 3, foods containing these are excellent as diabetes prevention foods.

【0062】[0062]

【発明の効果】本発明に係わるアラゲキクラゲの子実体
の水抽出物、またはアコヤ貝貝殻粉末を配合した抗糖尿
病剤および分離精製した抗糖尿病剤は、糖尿病に対し
て、過食、多飲の改善効果、空腹時血糖の上昇抑制効
果、食後高血糖の抑制効果、尿糖排泄の減少効果、耐糖
能低下の改善効果、インスリン抵抗性の改善効果、小腸
二糖類水解酵素活性の抑制効果を有しているので、糖尿
病の治療のみならず発症防止、又は抑制に用いることが
できる。糖尿病患者および糖尿病予備軍の人にとって非
常に有用である。また、原料が食糧となっている天然物
質由来の抽出物であるため、人体への安全性が高い。
EFFECT OF THE INVENTION The anti-diabetic agent containing the water extract of the fruit body of the mushroom jellyfish or the pearl oyster shell powder according to the present invention and the isolated and purified anti-diabetic agent are effective in improving overeating and heavy drinking against diabetes. It has the effect of suppressing fasting blood glucose elevation, suppressing postprandial hyperglycemia, reducing urinary glucose excretion, improving glucose tolerance, improving insulin resistance, and suppressing intestinal disaccharide hydrolase activity. Therefore, it can be used not only for treating diabetes but also for preventing or suppressing the onset of diabetes. Very useful for diabetics and those in the reserve. In addition, since the raw material is an extract derived from a natural substance used as food, it is highly safe for the human body.

【0063】本発明の糖尿病予防食品は、上記抗糖尿病
剤が食品中に単独であるいは混合物として配合されてい
るので、人体への安全性が高く、かつ糖尿病の治療のみ
ならず発症防止、または抑制に有用である。
Since the anti-diabetic agent of the present invention contains the above-mentioned anti-diabetic agent alone or as a mixture in the food, it is highly safe for the human body and not only treats diabetes but also prevents or suppresses the onset of diabetes. Useful for

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A23L 2/38 A61K 35/56 A61K 35/56 A61P 3/10 A61P 3/10 A23L 2/00 F Fターム(参考) 4B017 LC03 LG15 LK17 4B018 MD75 MD82 ME03 MF01 4B036 LC06 LF01 LH34 LH37 4C087 AA01 AA02 BB16 MA43 MA52 NA14 ZC35 4C088 AA03 AC17 BA09 CA08 CA19 MA43 MA52 NA14 ZC35 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A23L 2/38 A61K 35/56 A61K 35/56 A61P 3/10 A61P 3/10 A23L 2/00 F F-term (Reference) 4B017 LC03 LG15 LK17 4B018 MD75 MD82 ME03 MF01 4B036 LC06 LF01 LH34 LH37 4C087 AA01 AA02 BB16 MA43 MA52 NA14 ZC35 4C088 AA03 AC17 BA09 CA08 CA19 MA43 MA52 NA14 ZC35

Claims (5)

【特許請求の範囲】[Claims] 【請求項1】 アラゲキクラゲ(Auricularia polytric
ha)の子実体の水抽出物を配合した抗糖尿病剤。
1. A jellyfish (Auricularia polytric)
ha) An antidiabetic agent containing an aqueous extract of fruiting bodies.
【請求項2】 アラゲキクラゲ(Auricularia polytric
ha)の子実体の水抽出物に由来する水溶性多糖類を配合
した抗糖尿病剤。
2. A jellyfish (Auricularia polytric)
An antidiabetic agent containing a water-soluble polysaccharide derived from the water extract of the fruiting body of ha).
【請求項3】 前記水溶性多糖類は、アラゲキクラゲ
(Auricularia polytricha)の子実体の水抽出液に、水
溶性有機溶媒あるいは水溶性有機溶媒と水の混合溶媒を
加えて沈殿した沈殿物であることを特徴とする請求項2
記載の抗糖尿病剤。
3. The water-soluble polysaccharide is a precipitate obtained by adding a water-soluble organic solvent or a mixed solvent of a water-soluble organic solvent and water to an aqueous extract of a fruit body of Auricularia polytricha. 3. The method according to claim 2, wherein
The antidiabetic agent according to the above.
【請求項4】 アコヤ貝(Pinctada fucata)の貝殻粉
末を配合した抗糖尿病剤。
4. An antidiabetic agent containing shell powder of pearl oyster (Pinctada fucata).
【請求項5】 請求項1ないし請求項4のいずれか一項
記載の抗糖尿病剤が食品中に配合された糖尿病予防食
品。
5. A diabetes-preventive food, wherein the antidiabetic agent according to any one of claims 1 to 4 is incorporated in the food.
JP2001074766A 2001-03-15 2001-03-15 Antidiabetic medicine and food for preventing diabetes Pending JP2002275087A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001074766A JP2002275087A (en) 2001-03-15 2001-03-15 Antidiabetic medicine and food for preventing diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001074766A JP2002275087A (en) 2001-03-15 2001-03-15 Antidiabetic medicine and food for preventing diabetes

Publications (1)

Publication Number Publication Date
JP2002275087A true JP2002275087A (en) 2002-09-25

Family

ID=18931968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001074766A Pending JP2002275087A (en) 2001-03-15 2001-03-15 Antidiabetic medicine and food for preventing diabetes

Country Status (1)

Country Link
JP (1) JP2002275087A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003081750A (en) * 2001-09-14 2003-03-19 Mikimoto Pharmaceut Co Ltd Cosmetic or food
JP2007306892A (en) * 2006-05-22 2007-11-29 Aaresu:Kk Beautiful skin health tea, and method for producing the same
JP2008178363A (en) * 2007-01-25 2008-08-07 Tohoku Univ Model animal with leptin signal transduction failure
JP2013059332A (en) * 2012-10-26 2013-04-04 Tohoku Univ Method for analyzing sensitivity of obesity or diabetes onset to social isolation during growing stage of mouse
CN103445140A (en) * 2013-07-15 2013-12-18 闽南师范大学 Auricularia polytricha antioxidant additive and preparation method thereof
JP2018057307A (en) * 2016-10-04 2018-04-12 千葉真知子クッキングスタジオ有限会社 Granular health food
CN108727474A (en) * 2018-06-11 2018-11-02 北京市农林科学院 Uricularia polytricha extract with the fat liver-protecting function that disappears and its application
CN110106216A (en) * 2019-05-25 2019-08-09 孙海 A kind of extracting method of Polysaccharide from Auricularia Polytricha Sacc

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183537A (en) * 1987-07-22 1988-07-28 Nonogawa Shoji:Kk Anti-inflammatory agent
JPH0253459A (en) * 1988-08-19 1990-02-22 Maruzen Kasei Co Ltd Water-soluble dietary fiber
JPH04124139A (en) * 1990-09-12 1992-04-24 Itouen:Kk Hypoglycemically functioning agent and its production
JPH0567A (en) * 1991-06-20 1993-01-08 Towa Kasei Kogyo Kk Calcium-and dietary-fiber containing food and drink and production thereof
JPH07147935A (en) * 1993-11-26 1995-06-13 Meiji Seika Kaisha Ltd Food for diet-diabetes
JPH0967268A (en) * 1995-08-29 1997-03-11 New Food Kurieeshiyon Gijutsu Kenkyu Kumiai Suppressant for hyperglycemia and food and drink
JPH09241172A (en) * 1996-03-04 1997-09-16 Kagome Co Ltd Physiologically active agent
JPH10262609A (en) * 1997-03-19 1998-10-06 Kazuo Minotani Processing of eggshell of bird
JPH11209225A (en) * 1998-01-21 1999-08-03 Leap:Kk Usage of shellfish

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183537A (en) * 1987-07-22 1988-07-28 Nonogawa Shoji:Kk Anti-inflammatory agent
JPH0253459A (en) * 1988-08-19 1990-02-22 Maruzen Kasei Co Ltd Water-soluble dietary fiber
JPH04124139A (en) * 1990-09-12 1992-04-24 Itouen:Kk Hypoglycemically functioning agent and its production
JPH0567A (en) * 1991-06-20 1993-01-08 Towa Kasei Kogyo Kk Calcium-and dietary-fiber containing food and drink and production thereof
JPH07147935A (en) * 1993-11-26 1995-06-13 Meiji Seika Kaisha Ltd Food for diet-diabetes
JPH0967268A (en) * 1995-08-29 1997-03-11 New Food Kurieeshiyon Gijutsu Kenkyu Kumiai Suppressant for hyperglycemia and food and drink
JPH09241172A (en) * 1996-03-04 1997-09-16 Kagome Co Ltd Physiologically active agent
JPH10262609A (en) * 1997-03-19 1998-10-06 Kazuo Minotani Processing of eggshell of bird
JPH11209225A (en) * 1998-01-21 1999-08-03 Leap:Kk Usage of shellfish

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Hypoglycemic Effect of Water-soluble Polysaccharide from Auricularia auricula-judae Quel. on Genetic", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 62, no. 10, JPN6010061623, 1998, pages 1898 - 1903, ISSN: 0001765066 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003081750A (en) * 2001-09-14 2003-03-19 Mikimoto Pharmaceut Co Ltd Cosmetic or food
JP2007306892A (en) * 2006-05-22 2007-11-29 Aaresu:Kk Beautiful skin health tea, and method for producing the same
JP4647546B2 (en) * 2006-05-22 2011-03-09 有限会社アーレス Beauty skin health tea and method for producing the same
JP2008178363A (en) * 2007-01-25 2008-08-07 Tohoku Univ Model animal with leptin signal transduction failure
JP2013059332A (en) * 2012-10-26 2013-04-04 Tohoku Univ Method for analyzing sensitivity of obesity or diabetes onset to social isolation during growing stage of mouse
CN103445140A (en) * 2013-07-15 2013-12-18 闽南师范大学 Auricularia polytricha antioxidant additive and preparation method thereof
JP2018057307A (en) * 2016-10-04 2018-04-12 千葉真知子クッキングスタジオ有限会社 Granular health food
CN108727474A (en) * 2018-06-11 2018-11-02 北京市农林科学院 Uricularia polytricha extract with the fat liver-protecting function that disappears and its application
CN108727474B (en) * 2018-06-11 2020-07-28 北京市农林科学院 Auricularia polytricha extract with fat reducing and liver protecting functions and application thereof
CN111704658A (en) * 2018-06-11 2020-09-25 北京市农林科学院 Auricularia polytricha glycopeptide with fat-reducing and liver-protecting functions and application thereof
CN110106216A (en) * 2019-05-25 2019-08-09 孙海 A kind of extracting method of Polysaccharide from Auricularia Polytricha Sacc

Similar Documents

Publication Publication Date Title
JP3585778B2 (en) Nori enzymatically decomposed composition and use thereof
JP2006045212A (en) Oral composition containing specific quinic acid derivative
TWI239245B (en) Medical composition for oral administration or intravenous administration for a disease requiring enhancement of nerve growth factor production for treatment or prevention
JP4917584B2 (en) Processed solubilized bees, method for producing the same, antioxidant, ACE inhibitor, antihypertensive agent, dermal fibroblast proliferation promoter, fatigue recovery agent, blood flow improving agent, and solubilized bees Pharmaceuticals, cosmetics or food / drinks contained
JP2002275087A (en) Antidiabetic medicine and food for preventing diabetes
JP2006273840A (en) Rice protein composition and its use
JP3691685B2 (en) Blood sugar level rise inhibitor
JP2003292444A (en) Insulin secretion promoting agent
WO2004039368A1 (en) Peroral preparation for prevention of or treatment for atopic dermatitis
JP4673071B2 (en) Iron-adsorptive polymer substance, iron-containing polymer substance, and production method thereof
CN106573034B (en) Marine peptides and fish nucleotides, compositions and uses thereof for lowering blood glucose
CN1184902C (en) Liver-protecting functional food made up by using ligustrum fruit and silkworm chrysalis and its preparation method
JP2002255832A (en) Mineral absorption-promoting agent and anemia- improving agent
JPWO2008123417A1 (en) Anti-fatigue
JP2001048794A (en) Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm
JP2009084191A (en) Pharmaceutical composition for inhibiting appetite
JP2000032924A (en) Maintenance and improvement of physical condition of horse
JP4524018B2 (en) Pharmaceutical composition and health food for prevention and treatment of non-insulin dependent diabetes mellitus comprising mulberry leaf and agaricus extract mixture
JP2019041687A (en) Composition for eating and drinking
JP5749469B2 (en) Antihypertensive
JP3993907B2 (en) Calcium absorption promoter
JP2010006748A (en) Dipeptidyl peptidase iv inhibitor
KR100679698B1 (en) An extract of Pterocarya paliurus with blood sugar level-lowering activity and functional food comprising the same
JPWO2007004570A1 (en) Composition having improved endurance and / or anti-fatigue action
JP5265177B2 (en) Composition for improving bowel movements containing acacia bark

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719